Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exscientia Plc - American Depositary Shares (NQ:EXAI)

4.840 UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exscientia Plc - American Depositary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
"Our Mission Is To Eliminate Cancer" – Here's How This Company Is Using AI In An Attempt To Save Lives
Photo by National Cancer Institute on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Professor Charlotte Deane Joins Exscientia as Chief Scientist of Biologics AI
From Exscientia
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Absci (NASDAQ:ABSI) shares increased by 51.5% to $9.3 during Friday's pre-market session. The market value of their outstanding shares is at $861.1 million.... 
Via Benzinga
Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines
From Exscientia
Via Business Wire
Three Analysts Initiate Coverage On This AI-Based Pharmatech
BofA 
Via Benzinga
Exscientia to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference
From Exscientia
Via Business Wire
Exscientia Business Update for Third Quarter 2021
From Exscientia
Via Business Wire
Exscientia to Report Third Quarter 2021 Financial Results on November 17, 2021
From Exscientia
Via Business Wire
Publication of EXALT-1 Trial in Cancer Discovery Demonstrates First AI-Supported Functional Precision Medicine Platform to Improve Cancer Treatment Outcomes
From Exscientia
Via Business Wire
Earnings Scheduled For November 17, 2021
Companies Reporting Before The Bell • ZIM Integrated Shipping (NYSE:ZIM) is projected to report quarterly earnings at $9.25 per share on revenue of $2.77 billion.... 
Via Benzinga
Exscientia Announces Closing of $510.4 Million Aggregate Financing, Consisting of $350.4 Million Upsized Initial Public Offering With Full Exercise of Underwriters’ Option to Purchase Additional ADSs and $160.0 Million Concurrent Private Placement
From Exscientia
Via Business Wire
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Ocugen (NASDAQ:OCGN) shares moved upwards by 11.11% to $7.5 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.4... 
Via Benzinga
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exscientia Announces Pricing of $304.7 Million Upsized Initial Public Offering and $160.0 Million Concurrent Private Placements
From Exscientia plc Exscientia
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.